The Summary
In a 48-week randomized phase 2 trial, researchers evaluated 507 adults with obesity to test the safety and efficacy of combining semaglutide (a GLP-1 agonist) with bimagrumab (an antibody targeting activin receptors to promote muscle growth while reducing fat). Participants receiving the high-dose combination lost an average of 17.8 kg (about 39 pounds), compared to 14.2 kg with semaglutide alone, 9.3 kg with bimagrumab alone, and 3.3 kg with placebo. Side effects included muscle spasms and acne for bimagrumab, and gastrointestinal issues for semaglutide. Benefits persisted through a 72-week extension.
Why this is interesting
Traditional weight management treatments often cause patients to lose valuable muscle along with fat. Bimagrumab flips this script by blocking activin receptors to actively build muscle while burning fat. By combining it with semaglutide, this study shows we can achieve unprecedented fat loss without the typical muscle wasting. For the average reader, this represents a major step toward healthier, more sustainable body composition therapy, ensuring that the weight we lose is actually the bad kind (visceral fat) while keeping the strength we need to stay active.